Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 91 entries
Sorted by: Best Match Show Resources per page
Pathophysiology of Hemophilic Arthropathy.

Journal of clinical medicine

Melchiorre D, Manetti M, Matucci-Cerinic M.
PMID: 28672826
J Clin Med. 2017 Jun 25;6(7). doi: 10.3390/jcm6070063.

Spontaneous joint bleeding and repeated hemarthroses lead to hemophilic arthropathy-a debilitating disease with a significant negative impact on mobility and quality of life. Iron, cytokines, and angiogenic growth factors play a pivotal role in the onset of the inflammatory...

Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications.

Journal of clinical medicine

Manetti M, Romano E, Rosa I, Fioretto BS, Praino E, Guiducci S, Iannone F, Ibba-Manneschi L, Matucci-Cerinic M.
PMID: 31430950
J Clin Med. 2019 Aug 19;8(8). doi: 10.3390/jcm8081256.

Systemic sclerosis (SSc; scleroderma) is characterized by life-threatening progressive multiorgan fibrosis orchestrated by profibrotic myofibroblasts originating from different sources. Because recent data demonstrated that the majority of myofibroblasts in a murine scleroderma model arise from adipocytic progenitors through the...

Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis.

Orthopedic research and reviews

Migliore A, Gigliucci G, Alekseeva L, Bannuru RR, Blicharski T, Diracoglu D, Georgiadis A, Hamoud H, Martusevich N, Matucci Cerinic M, Perduk J, Szerb I, Trč T, Chevalier X.
PMID: 34880685
Orthop Res Rev. 2021 Dec 02;13:255-273. doi: 10.2147/ORR.S336185. eCollection 2021.

Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful...

Oral .

Microorganisms

Melchiorre D, Ceccherini MT, Romano E, Cometi L, El-Aoufy K, Bellando-Randone S, Roccotelli A, Bruni C, Moggi-Pignone A, Carboni D, Guiducci S, Lepri G, Tofani L, Pietramellara G, Matucci-Cerinic M.
PMID: 34203626
Microorganisms. 2021 Jun 15;9(6). doi: 10.3390/microorganisms9061298.

In systemic sclerosis (SSc), the gastrointestinal tract (GIT) plays a central role in the patient's quality of life. The microbiome populates the GIT, where a relationship between the

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.

The Lancet. Rheumatology

Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-Cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D.
PMID: 34966900
Lancet Rheumatol. 2020 Dec;2(12):e743-e753. doi: 10.1016/s2665-9913(20)30237-x. Epub 2020 Oct 19.

BACKGROUND: Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open-label extension for 6 months.METHODS: Patients...

Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.

Autoimmunity reviews

Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C, Pacini G, Moggi-Pignone A, Guiducci S, Bellando-Randone S, Shoenfeld Y, Dagna L, Matucci-Cerinic M.
PMID: 34718166
Autoimmun Rev. 2021 Dec;20(12):102981. doi: 10.1016/j.autrev.2021.102981. Epub 2021 Oct 28.

INTRODUCTION: Intravenous immunoglobulins (IVIG) are a new therapeutic approach in systemic sclerosis SSc. An immunomodulatory and antifibrotic activity has been postulated. IVIG are generally well tolerated and have only rare side effects. Our retrospective study focused its attention on...

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.

Turkish journal of medical sciences

Tufan A, Matucci-Cerinic M.
PMID: 34844296
Turk J Med Sci. 2021 Dec 17;51:3391-3404. doi: 10.3906/sag-2110-179.

In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus...

A special European Journal of Rheumatology issue on systemic sclerosis: What and why?.

European journal of rheumatology

Del Galdo F, Matucci-Cerinic M.
PMID: 33164730
Eur J Rheumatol. 2020 Oct;7:S137-S138. doi: 10.5152/eurjrheum.2020.090121. Epub 2020 Oct 01.

No abstract available.

Systemic sclerosis: To subset or not to subset, that is the question.

European journal of rheumatology

Johnson SR, van den Hoogen F, Devakandan K, Matucci-Cerinic M, Pope JE.
PMID: 33164736
Eur J Rheumatol. 2020 Oct;7:S222-S227. doi: 10.5152/eurjrheum.2020.19116. Epub 2020 Jul 06.

Systemic sclerosis (SSc) is a heterogeneous disease with variability in autoantibody profiles, skin and internal organ involvement, disease trajectory, and survival. The ability to identify more homogeneous subsets of SSc patients has informed patient care and been an essential...

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.

Journal of clinical medicine

Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, Morandi V, Meyer A, Pereira da Silva JA, Matos Costa CJ, Molberg O, Andersson H, Codullo V, Mosca M, Barsotti S, Neri R, Scirè C, Govoni M, Furini F, Lopez-Longo FJ, Martinez-Barrio J, Schneider U, Lorenz HM, Doria A, Ghirardello A, Ortego-Centeno N, Confalonieri M, Tomietto P, Pipitone N, Rodriguez Cambron AB, Blázquez Cañamero MÁ, Voll RE, Wendel S, Scarpato S, Maurier F, Limonta M, Colombelli P, Giannini M, Geny B, Arrigoni E, Bravi E, Migliorini P, Mathieu A, Piga M, Drott U, Delbrueck C, Bauhammer J, Cagnotto G, Vancheri C, Sambataro G, De Langhe E, Sainaghi PP, Monti C, Gigli Berzolari F, Romano M, Bonella F, Specker C, Schwarting A, Villa Blanco I, Selmi C, Ceribelli A, Nuno L, Mera-Varela A, Perez Gomez N, Fusaro E, Parisi S, Sinigaglia L, Del Papa N, Benucci M, Cimmino MA, Riccieri V, Conti F, Sebastiani GD, Iuliano A, Emmi G, Cammelli D, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Paolazzi G, Saketkoo LA, Giorgi R, Salaffi F, Cifrian J, Caporali R, Locatelli F, Marchioni E, Pesci A, Dei G, Pozzi MR, Claudia L, Distler J, Knitza J, Schett G, Iannone F, Fornaro M, Franceschini F, Quartuccio L, Gerli R, Bartoloni E, Bellando Randone S, Zampogna G, Gonzalez Perez MI, Mejia M, Vicente E, Triantafyllias K, Lopez-Mejias R, Matucci-Cerinic M, Selva-O'Callaghan A, Castañeda S, Montecucco C, Gonzalez-Gay MA.
PMID: 31752231
J Clin Med. 2019 Nov 18;8(11). doi: 10.3390/jcm8112013.

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases...

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience.

Therapeutic advances in musculoskeletal disease

Tesei G, Cometi L, Nacci F, Terenzi R, Tofani L, Capassoni M, Bartoli F, Fiori G, Matucci-Cerinic M, Bruni C.
PMID: 34025783
Ther Adv Musculoskelet Dis. 2021 May 10;13:1759720X211014019. doi: 10.1177/1759720X211014019. eCollection 2021.

BACKGROUND: Ultrasound (US) is useful in monitoring RA patients, with the US7 score allowing grey-scale and power-Doppler (PD) semi-quantitative evaluation of synovitis and teno-synovitis. We evaluated real-life efficacy and safety of Baricitinib, an oral selective JAK1-2 inhibitor, in RA...

Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis.

European journal of clinical investigation

d'Alessandro M, Bellisai F, Bergantini L, Cameli P, D'Alessandro R, Mazzei MA, Gentili F, Conticini E, Selvi E, Frediani B, Matucci-Cerinic M, Bargagli E.
PMID: 33759179
Eur J Clin Invest. 2021 Aug;51(8):e13543. doi: 10.1111/eci.13543. Epub 2021 Mar 23.

BACKGROUND: Krebs von den Lungen-6 (KL-6) is a high-molecular-weight (200kDa) glycoprotein proposed as a diagnostic biomarker for differentiating interstitial lung disease (ILD). Systemic sclerosis (SSc) is a rare immune-mediated disorder, and ILD is the leading cause of morbidity and...

Showing 1 to 12 of 91 entries